NEW YORK (GenomeWeb News) – BioTime has raised a further $4 million through the second tranche of a private placement of its common stock and purchase warrants.

The Alameda, Calif.-based firm said that Broadwood Partners and George Karfunkel have each purchased 1.1 million common shares in the firm as well as 1.1 million stock purchase warrants. The warrants are "substantially the same" as BioTime's publicly traded stock purchase warrants, the firm said, and entitles holders to purchase additional common shares at an exercise price of $2 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.